[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Carayol N, Crampette L, Mainprice B, Ben-Soussen P, Verrecchia M, Bousquet J, Lebel B: Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine. Allergy; 2002 Nov;57(11):1067-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine.
  • [MeSH-major] Antibodies, Anti-Idiotypic / therapeutic use. Benzimidazoles / therapeutic use. Cytokines / drug effects. Cytokines / metabolism. Histamine H1 Antagonists / therapeutic use. Inflammation Mediators / metabolism. Nasal Polyps / drug therapy. Nasal Polyps / metabolism. Neoplastic Cells, Circulating / drug effects
  • [MeSH-minor] Adult. Cell Survival / drug effects. Dose-Response Relationship, Drug. Epithelial Cells / cytology. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Female. Humans. Leukocytes / cytology. Leukocytes / drug effects. Leukocytes / metabolism. Male. Mast Cells / cytology. Mast Cells / drug effects. Mast Cells / metabolism. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12359006.001).
  • [ISSN] 0105-4538
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Benzimidazoles; 0 / Cytokines; 0 / Histamine H1 Antagonists; 0 / Inflammation Mediators; 0 / anti-IgE antibodies; 244O1F90NA / mizolastine
  •  go-up   go-down


2. Shailubhai K, Yu HH, Karunanandaa K, Wang JY, Eber SL, Wang Y, Joo NS, Kim HD, Miedema BW, Abbas SZ, Boddupalli SS, Currie MG, Forte LR: Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res; 2000 Sep 15;60(18):5151-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP.
  • Oral replacement therapy with human uroguanylin was used to evaluate its effects on the formation of intestinal polyps in the Min/+ mouse model for colorectal cancer.
  • The intestinal R-GC signaling molecules for guanylin regulatory peptides are promising targets for prevention and/or therapeutic treatment of intestinal polyps and cancers by oral administration of human uroguanylin.
  • [MeSH-major] Adenocarcinoma / pathology. Adenomatous Polyposis Coli / prevention & control. Apoptosis / drug effects. Colonic Neoplasms / pathology. Cyclic GMP / physiology. Gastrointestinal Hormones. Peptides / pharmacology
  • [MeSH-minor] Aged. Aged, 80 and over. Amino Acid Sequence. Animals. Caco-2 Cells / drug effects. Down-Regulation / drug effects. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Mice. Mice, Inbred C57BL. Middle Aged. Molecular Sequence Data. Natriuretic Peptides. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Cell Surface / biosynthesis. Receptors, Cell Surface / genetics. Receptors, Cell Surface / physiology. Tumor Cells, Cultured

  • Jackson Laboratory JAX®Mice Database. culture/stock collections - C57BL/6J-Apc<Min>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11016642.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Gastrointestinal Hormones; 0 / Natriuretic Peptides; 0 / Peptides; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 140653-38-9 / guanylin; 152175-68-3 / uroguanylin; H2D2X058MU / Cyclic GMP
  •  go-up   go-down


3. Li WW, Yau TN, Leung CW, Pong WM, Chan MY: Large-cell neuroendocrine carcinoma of the uterine cervix complicating pregnancy. Hong Kong Med J; 2009 Feb;15(1):69-72
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large-cell neuroendocrine cervical carcinoma is a rare and aggressive cancer that tends to spread and recur early despite intensive multimodal treatment.
  • The optimal mode of therapy is still controversial and management during pregnancy is challenging because foetal well-being must also be considered.
  • We report a patient with clinically stage IIB large-cell neuroendocrine cervical carcinoma who presented with a cervical polyp and vaginal bleeding at 18 weeks of pregnancy.
  • The patient received concurrent chemotherapy and radiation after termination of pregnancy and remained in complete remission 21 months after completion of treatment.


Advertisement
4. Niv Y: Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer. World J Gastroenterol; 2007 Mar 28;13(12):1767-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are more prevalent in the proximal colon and have a fast pass from polyp to cancer.
  • Resistance of colorectal cancers with a high frequency of microsatellite instability to 5-fluorouracil-based chemotherapy is well established.
  • Better knowledge of this process will have a huge impact on colorectal cancer management, prevention, treatment and prognosis.
  • [MeSH-minor] Cell Proliferation. DNA Methylation. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Promoter Regions, Genetic / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465465.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Nuclear Proteins
  • [Number-of-references] 24
  • [Other-IDs] NLM/ PMC4149951
  •  go-up   go-down


5. Morimoto LM, Newcomb PA, Ulrich CM, Bostick RM, Lais CJ, Potter JD: Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? Cancer Epidemiol Biomarkers Prev; 2002 Oct;11(10 Pt 1):1012-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases with hyperplastic polyps (n = 219), adenomas (n = 437), and both types of polyps (n = 138), along with colonoscopy-negative controls (n = 708), were identified at a gastroenterology practice in the Minneapolis area during 1991-1994.
  • Male sex, smoking, and alcohol consumption were associated with increased risk of all polyp groups; nonsteroidal anti-inflammatory drug use, hormone replacement therapy use, and calcium intake were associated with reduced risk.
  • There was no apparent association between increasing age and hyperplastic polyp risk (P = 0.21) in this analysis, although it was a strong risk factor for adenoma (P < 0.001).
  • The OR estimate for individuals diagnosed with both polyp types was 4.2 (95% CI, 1.9-9.3).
  • To the contrary, individuals with both polyp types may be expressing a phenotype distinct from those who have only adenomas and should be considered separately.
  • Further studies are necessary to establish which polyp phenotypes are related to smoking.
  • Overall, the similarity of the risk profiles of colorectal hyperplastic polyps, adenoma, and cancer provides additional support for the growing body of evidence that some hyperplastic polyps may have neoplastic potential.
  • [MeSH-minor] Adult. Aged. Alcohol Drinking / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Case-Control Studies. Female. Hormone Replacement Therapy / adverse effects. Humans. Hyperplasia. Male. Middle Aged. Phenotype. Risk Factors. Sex Factors

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12376501.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5-T32-CA09168; United States / NIEHS NIH HHS / ES / ES-07033; United States / NCI NIH HHS / CA / P01 CA 50405; United States / NCI NIH HHS / CA / T32 CA09661
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


6. Yamamasu S, Nakai Y, Nishio J, Hyun Y, Honda KI, Hirai K, Ishiko O, Ogita S: Conservative management of placental polyp with oral administration of methotrexate. Oncol Rep; 2001 Sep-Oct;8(5):1031-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative management of placental polyp with oral administration of methotrexate.
  • Surgical treatment is usually selected for placental polyp accompanied by massive bleeding but patients wishing to conserve their fecundity require conservative management.
  • A 35-year old nullipara was diagnosed as having placental polyp on the basis of typical episodes, and detection of placental polypeptide hormones and blood flow by Doppler ultrasonography and dynamic magnetic resonance imaging.
  • Oral administration of methotrexate (2.5 mg, three times a day for 5 days) was repeated for three cycles because surgical treatment was rejected.
  • Serum human placental lactogen, blood flow and the polyp disappeared sequentially following chemotherapy.
  • This report thus advocates considering conservative management for placental polyp.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Methotrexate / administration & dosage. Placenta Diseases / drug therapy. Polyps / drug therapy. Pregnancy Complications, Neoplastic / drug therapy

  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11496311.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Chorionic Gonadotropin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Rossi G, Bonacorsi G, Longo L, Artusi T, Rivasi F: Primary high-grade mucosa-associated lymphoid tissue-type lymphoma of the cervix presenting as a common endocervical polyp. Arch Pathol Lab Med; 2001 Apr;125(4):537-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary high-grade mucosa-associated lymphoid tissue-type lymphoma of the cervix presenting as a common endocervical polyp.
  • We describe a rare case of primary high-grade lymphoma of mucosa-associated lymphoid tissue of the uterine cervix in a 46-year-old white woman.
  • The tumor, incidentally disclosed at gynecological examination, appeared as a single common polyp.
  • The neoplastic cells did not stain for CD5, CD10, CD23, CD43, or cyclin D1.
  • The tumor was successfully treated by multiagent chemotherapy followed by total hysterectomy.
  • To our knowledge, this case represents the second reported example of mucosa-associated lymphoid tissue-type lymphoma occurring in the uterine cervix.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Bleomycin. Cyclophosphamide. Cytarabine. Diagnosis, Differential. Epirubicin. Etoposide. Female. Humans. Hysterectomy. Immunohistochemistry. In Situ Hybridization. Methotrexate. Middle Aged. Neoplasm Proteins / analysis. Prednisone. Vincristine


8. Ohwada M, Suzuki M, Hironaka M, Irie T, Sato I: Neuroendocrine small cell carcinoma of the uterine cervix showing polypoid growth and complicated by pregnancy. Gynecol Oncol; 2001 Apr;81(1):117-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No polyp had been detected at 14 weeks of gestation.
  • The polyp was excised and diagnosed as neuroendocrine small cell carcinoma by histological examination, including Grimelius, neuron-specific enolase, and chromogranin staining.
  • After surgery, four cycles of combination chemotherapy with cisplatin and etoposide were administered, and the patient is disease-free as of 13 months after surgery.
  • CONCLUSION: When a polypoid lesion is found, especially when it demonstrates rapid growth, it may be necessary to excise and histologically examine the polyp even during pregnancy.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Pregnancy Complications, Neoplastic / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Division / physiology. Female. Humans. Polyps / drug therapy. Polyps / pathology. Polyps / surgery. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11277662.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


9. Chmiel B, Nocoń G: [Secondary primary, bilocal sigmoid colon adenocarcinoma in a patient previously treated for testicular cancer]. Wiad Lek; 2004;57(5-6):288-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Frequency of neoplastic diseases among patients cured successfully from testicular cancer is higher than in normal population.
  • The patient underwent nearly total colectomy and resection of the rectal polyp.
  • Six months after operation patient did not present any features of neoplastic disease.
  • This case is an illustration of the problem of cancerogenesis within polyps of the large bowel in patients treated before by chemotherapy because of testicular cancer.
  • [MeSH-minor] Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15518079.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


10. Chandacham A, Kietpeerakool C, Khunamornpong S, Suprasert P, Srisomboon J, Charoenkwan K, Phongnarisorn C, Cheewakraingkrai C, Siriaree S, Tantipalakorn C: Successfully conservative treatment of large cervical choriocarcinoma with profuse vaginal bleeding. J Med Assoc Thai; 2009 Jan;92(1):120-3
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successfully conservative treatment of large cervical choriocarcinoma with profuse vaginal bleeding.
  • Furthermore, the majority of cases presented with abnormal vaginal bleeding that could be caused by other more common conditions including, threatened abortion, cervical polyp, cervical pregnancy, or cervical cancer.
  • Remission of cervical choriocarcinoma was accomplished with combination chemotherapy without the need of hysterectomy.
  • [MeSH-major] Choriocarcinoma / therapy. Pregnancy Complications, Neoplastic / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Diagnosis, Differential. Embolization, Therapeutic. Etoposide / administration & dosage. Female. Humans. Mitoxantrone / administration & dosage. Pregnancy. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260253.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; MEA protocol
  •  go-up   go-down


11. Goldstein PJ, Cabanas J, da Silva RG, Sugarbaker PH: Pseudomyxoma peritonei arising from colonic polyps. Eur J Surg Oncol; 2006 Sep;32(7):764-6
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This manuscript describes this disease arising from a benign or malignant colonic polyp.
  • METHODS: From a database of over 1000 pseudomyxoma peritonei patients and colorectal carcinomatosis patients, three cases were identified in which the primary tumor site was a colonic polyp.
  • RESULTS: In a review of the clinical management of these patients, all three had an event whereby neoplastic cells from the surface of the colonic polyp could have gained access to the free peritoneal cavity.
  • The patients developed the characteristic pseudomyxoma peritonei syndrome.
  • All three patients were treated with cytoreductive surgery plus perioperative hyperthermic intraperitoneal chemotherapy.
  • If pseudomyxoma peritonei develops, cytoreductive surgery and perioperative intraperitoneal chemotherapy should be considered for treatment.

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765563.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Kuhne HP, Göller T, Schneider I, Bozkurt T, Becker HP: [Unclear per anum bleeding during pregnancy]. Chirurg; 2005 Aug;76(8):765-8
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rectoscopy showed the cause to be a polyp the size of a fingertip 9 cm from the anus.
  • Seeking a prognosis optimal for the newborn child, the interdisciplinary decision was made for primary surgery with adjuvant chemotherapy.
  • [MeSH-major] Intestinal Polyps / diagnosis. Melena / etiology. Neuroendocrine Tumors / diagnosis. Pregnancy Complications / etiology. Pregnancy Complications, Neoplastic / diagnosis. Puerperal Disorders / diagnosis. Rectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • MedlinePlus Health Information. consumer health - Postpartum Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Q J Nucl Med Mol Imaging. 2004 Jun;48(2):150-63 [15243410.001]
  • [Cites] Tumori. 2000 Jan-Feb;86(1):95-7 [10778777.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Am J Surg Pathol. 1990 Nov;14(11):1010-23 [2173427.001]
  • [Cites] Drug Saf. 1998 Feb;18(2):135-42 [9512920.001]
  • (PMID = 15971036.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Goel A, Fuerst F, Hotchkiss E, Boland CR: Selenomethionine induces p53 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cancer Biol Ther; 2006 May;5(5):529-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While there is an increasing interest in selenium chemoprevention against human colon polyp recurrence and other cancers, the mechanism(s) by which these agents inhibit carcinogenesis are uncertain.
  • However, the molecular mechanisms of action of selenomethionine, an organoselenium compound present in selenized yeast and currently being investigated in human clinical trials for colon polyp prevention, are unclear.
  • Four human colon cancer cell lines including HCT116 and RKO (wild type p53), HCT116-p53KO (isogenic control of HCT116 cells with p53 knocked out) and Caco-2 (mutant p53) were treated with 0-100 microM of selenomethionine for 24, 48 and 72 h.
  • All cell lines showed concentration and time dependent growth inhibition with selenomethionine, although HCT116 and RKO cells were the most sensitive to such treatments.
  • Cell cycle arrest and apoptosis observed in HCT116 and RKO cell lines were accompanied by a marked increase in p53 protein expression following selenium treatment.
  • [MeSH-major] Apoptosis / drug effects. Cell Division / drug effects. Colonic Neoplasms / metabolism. G2 Phase / drug effects. Selenomethionine / pharmacology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Blotting, Western. Cell Proliferation / drug effects. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. SELENIUM METHIONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627976.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA 72851
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 964MRK2PEL / Selenomethionine
  •  go-up   go-down


14. Mbatsogo BA, Le Bouëdec G, Michy T, Bourdel N, Fouilloux G, Dauplat J: [Endometrial cancers arising in polyps associated with tamoxifen use]. Gynecol Obstet Fertil; 2005 Dec;33(12):975-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A malignant transformation of polyp was found in 5 instances, meaning a rate of 4.6% i.e.
  • DISCUSSION AND CONCLUSION: The existence of endometrial polyps - symptomatic or not - does not seem compatible with the prolonged use of tamoxifen treatment owing the estrogen agonist potential effects of tamoxifen and its well-known hyperplastic and carcinogenic properties for the endometrium.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Cell Transformation, Neoplastic / chemically induced. Endometrial Neoplasms / chemically induced. Polyps / pathology. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Aged, 80 and over. Breast Neoplasms / drug therapy. Female. Humans. Middle Aged. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321556.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 44
  •  go-up   go-down


15. Bese T, Simsek Y, Bese N, Ilvan S, Arvas M: Extensive pelvic endometriosis with malignant change in tamoxifen-treated postmenopausal women. Int J Gynecol Cancer; 2003 May-Jun;13(3):376-80
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 74-year-old woman with a history of breast carcinoma who received tamoxifen therapy for 2 years was admitted with uterine bleeding.
  • Hysteroscopic polypectomy revealed a hyperplastic polyp.
  • As cervical cancer occurred in a short period, it might be speculated that tamoxifen might have stimulated the proliferative and mitotic activity of cervical endometrial tissue which has progressed into invasive cancer in time.
  • [MeSH-major] Adenocarcinoma / chemically induced. Adnexal Diseases / complications. Antineoplastic Agents, Hormonal / adverse effects. Cell Transformation, Neoplastic / chemically induced. Endometriosis / complications. Tamoxifen / adverse effects. Uterine Cervical Neoplasms / chemically induced
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Female. Gynecologic Surgical Procedures / methods. Humans. Pelvis. Postmenopause


16. Zagani R, Hamzaoui N, Cacheux W, de Reyniès A, Terris B, Chaussade S, Romagnolo B, Perret C, Lamarque D: Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers. Gastroenterology; 2009 Oct;137(4):1358-66.e1-3
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.
  • We performed microarray analysis of adenomas from Apc(Delta14/+) mice to identify genes that respond to these drugs.
  • METHODS: Apc(Delta14/+) mice were given a single daily injection of parecoxib for up to 9 weeks; intestinal tracts of these and control mice were analyzed by microarray analysis, immunohistochemistry, in situ hybridization, and quantitative real-time polymerase chain reaction.
  • Apc(Delta14/+) mice given parecoxib had longer survival times and reduced polyp burdens.
  • These factors might be developed as therapeutic targets for intestinal cancers.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Antineoplastic Agents / pharmacology. Colonic Polyps / drug therapy. Colorectal Neoplasms / drug therapy. Cyclooxygenase 2 / metabolism. Cyclooxygenase Inhibitors / therapeutic use. DNA-Binding Proteins / metabolism. Osteopontin / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival. Down-Regulation. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Genes, APC. Humans. Isoxazoles / therapeutic use. Lactones / therapeutic use. Mice. Mice, Mutant Strains. Nuclear Receptor Subfamily 4, Group A, Member 2. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic. RNA Interference. Signal Transduction. Sulfones / therapeutic use. Time Factors. Transfection. Wnt Proteins / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549529.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CTNNB1 protein, mouse; 0 / Cyclooxygenase Inhibitors; 0 / DNA-Binding Proteins; 0 / Isoxazoles; 0 / Lactones; 0 / NR4A2 protein, human; 0 / Nr4a2 protein, mouse; 0 / Nuclear Receptor Subfamily 4, Group A, Member 2; 0 / SPP1 protein, human; 0 / Spp1 protein, mouse; 0 / Sulfones; 0 / Transcription Factors; 0 / Wnt Proteins; 0 / beta Catenin; 0QTW8Z7MCR / rofecoxib; 106441-73-0 / Osteopontin; 9TUW81Y3CE / parecoxib; EC 1.14.99.- / Ptgs2 protein, mouse; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


17. Qureshi A, Bukhari F, Pervez S: Spectrum of tamoxifen associated endometrial pathology in breast cancer patients. J Pak Med Assoc; 2009 Apr;59(4):249-50
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of the study was to determine the incidence and type of endometrial abnormalities in long-term users of tamoxifen with breast cancer.
  • All patients with a diagnosis of Oestrogen Receptor positive breast cancer on Tamoxifen therapy who had also undergone endometrial biopsy for abnormal bleeding or other symptoms were included.
  • There were seven cases of simple hyperplasia and thirteen of endometrial polyp.
  • These findings support the association between prolonged tamoxifen therapy and endometrial pathology of possible neoplastic potential.
  • [MeSH-major] Breast Neoplasms / drug therapy. Endometrium / drug effects. Endometrium / pathology. Estrogen Antagonists / adverse effects. Tamoxifen / adverse effects. Uterine Diseases / chemically induced


18. Song J, Sohn KJ, Medline A, Ash C, Gallinger S, Kim YI: Chemopreventive effects of dietary folate on intestinal polyps in Apc+/-Msh2-/- mice. Cancer Res; 2000 Jun 15;60(12):3191-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recently developed murine model of intestinal tumorigenesis, which carries a heterozygous mutation in the Apc gene and a null mutation in the Msh2 gene (Apc+/-Msh2-/-), was used to determine the effect of dietary folate on intestinal tumorigenesis.
  • The 3- and 6-week diet starts represent intervention before and after the establishment of neoplastic foci, respectively.
  • Microsatellite instability was determined in matched normal and polyp DNA from the small intestine and colon at 5 loci.
  • Folate supplementation, started before the establishment of neoplastic foci, significantly decreased the number of small intestinal adenomas (by 2.7-fold; P = 0.004) and colonic ACF (by 2.8-fold; P = 0.028) and colonic adenomas (by 2.8-fold; P = 0.1) compared with a moderate degree of folate deficiency.
  • In contrast, a moderately folate-deficient diet, started after the establishment of neoplastic foci, significantly reduced the number of small intestinal adenomas (by 4.2-fold; P = 0.001) but had no effect on colonic ACF and adenomas compared with folate supplementation.
  • In conclusion, in this murine model, dietary folate supplementation significantly protects against small intestinal and colorectal tumorigenesis if it is provided before the establishment of neoplastic foci However, if it is provided after the establishment of neoplastic foci, dietary folate seems to have an opposite effect.
  • [MeSH-major] Colorectal Neoplasms / prevention & control. DNA-Binding Proteins. Diet. Folic Acid / therapeutic use. Intestinal Polyps / drug therapy. Intestinal Polyps / prevention & control
  • [MeSH-minor] Adenoma / prevention & control. Adenomatous Polyposis Coli Protein. Age Factors. Animals. Body Weight / drug effects. Colon / drug effects. CpG Islands / genetics. Cytoskeletal Proteins / genetics. Intestine, Small / drug effects. Methylation. Mice. Mice, Inbred C57BL. Microsatellite Repeats. MutS Homolog 2 Protein. Precancerous Conditions / drug therapy. Precancerous Conditions / prevention & control. Proto-Oncogene Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10866310.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 935E97BOY8 / Folic Acid; EC 3.6.1.3 / Msh2 protein, mouse; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


19. Voutsadakis IA: Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med; 2007 Mar-Apr;11(2):252-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2.
  • Inhibition of Cox-2 by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been found to inhibit proliferation of colorectal cancer cells and in epidemiologic studies has been shown to reduce colon polyp formation in genetically predisposed populations and in the general population.
  • Targeted therapies, the result of increasingly understanding carcinogenesis in the molecular level, have entered the field of anti-neoplastic treatment and are used by themselves and in combination with chemotherapy drugs.
  • Combinations of targeted drugs have started also to be investigated.
  • This article reviews the molecular pathogenesis of colorectal cancer, the roles of UPS and Cox-2 in it and puts forward a rational for their combined inhibition in colorectal cancer treatment.
  • [MeSH-major] Carcinoma / therapy. Colorectal Neoplasms / therapy. Cyclooxygenase 2 / metabolism. Cyclooxygenase Inhibitors / therapeutic use. Proteasome Endopeptidase Complex / metabolism. Ubiquitin / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488476.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Ubiquitin; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Number-of-references] 298
  • [Other-IDs] NLM/ PMC3822826
  •  go-up   go-down


20. Rao CV, Swamy MV, Patlolla JM, Kopelovich L: Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. Cancer Res; 2008 Sep 15;68(18):7670-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The styrylquinazoline CP-31398 can rescue destabilized mutant p53 expression and promote activity of wild-type p53.
  • Effects of CP-31398 on early-stage adenomas were determined by feeding 7-week-old female C57BL/6J-APC(min) (heterozygous) and wild-type C57BL/6J mice with American Institute of Nutrition-76A diets containing 0, 100, or 200 ppm of CP-31398 for 75 days.
  • During late-stage intervention, CP-31398 also significantly suppressed intestinal polyp formation, albeit to a lesser extent than observed with early intervention.
  • These observations show for the first time that the p53-modulating agent CP-31398 possesses significant chemopreventive activity in vivo against intestinal neoplastic lesions in genetically predisposed APC(min/+) mice.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Jul 17;22(29):4478-87 [12881704.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):577-90 [12667443.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):371-81 [14667504.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):29-42 [14965265.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Trends Biotechnol. 2004 Sep;22(9):431-4 [15331219.001]
  • [Cites] Cell. 2007 Mar 9;128(5):837-40 [17350571.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3753-64 [18060030.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):285-91 [15491287.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45887-96 [15308639.001]
  • [Cites] J Natl Cancer Inst. 1986 Dec;77(6):1241-6 [3467115.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9 [1699228.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1033-8 [7576987.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):710-4 [8631000.001]
  • [Cites] Nat Med. 1996 Oct;2(10):1143-6 [8837616.001]
  • [Cites] Oncogene. 1996 Dec 5;13(11):2477-82 [8957091.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7370-7 [16849589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11003-8 [16835297.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] J Am Chem Soc. 2007 Mar 7;129(9):2456-7 [17284038.001]
  • [Cites] Science. 1999 Dec 24;286(5449):2507-10 [10617466.001]
  • [Cites] Oncogene. 2000 Mar 2;19(10):1245-56 [10713666.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):617-21 [10753194.001]
  • [Cites] Cell. 2000 Nov 22;103(5):691-4 [11114324.001]
  • [Cites] Nat Med. 2002 Mar;8(3):282-8 [11875500.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):68-76 [11900253.001]
  • [Cites] Exp Cell Res. 2002 Jun 10;276(2):214-22 [12027451.001]
  • [Cites] Cancer Biol Ther. 2002 Jan-Feb;1(1):47-55 [12174820.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):263-7 [12584176.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2171-81 [12612087.001]
  • [Cites] Cell. 2003 Mar 21;112(6):779-91 [12654245.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5239-42 [14500353.001]
  • (PMID = 18794156.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25114; United States / NCI NIH HHS / CA / R01 CA094962; United States / NCI NIH HHS / CA / R01 CA094962-05; United States / NCI NIH HHS / CA / CA094962-05; United States / NCI NIH HHS / CA / NCI-CA-94962
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CP 31398; 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Pyrimidines; 0 / Tumor Suppressor Protein p53; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS60489; NLM/ PMC2597360
  •  go-up   go-down


21. Stoehlmacher J, Lenz HJ: Cyclooxygenase-2 inhibitors in colorectal cancer. Semin Oncol; 2003 Jun;30(3 Suppl 6):10-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors are associated with decreased colorectal cancer incidence and mortality rate.
  • The inducible COX-2 isoform is overexpressed in colorectal tissues and is associated with critical events of tumorigenesis.
  • These data, together with the fact that COX-2 inhibitors cause less toxic side effects compared with nonselective nonsteroidal anti-inflammatory drugs, render these new compounds promising candidates in chemoprevention and treatment of colorectal cancer.
  • Results from initial clinical trials suggest that COX-2 inhibitors may be able to reduce the polyp burden in patients with familial polyposis coli.
  • However, further clinical studies are needed to evaluate whether COX-2 inhibition will be effective in all types of colorectal tumor tissues.
  • This is especially true for neoplastic lesions that express COX-2 at a lower level (eg, hereditary nonpolyposis colorectal cancer) and for colorectal tumors of patients with inflammatory bowel disease.
  • In summary, COX-2 inhibitors represent a new and very promising group of chemotherapeutic agents with great potential for both colorectal cancer prevention and treatment.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Cyclooxygenase Inhibitors / therapeutic use. Isoenzymes / antagonists & inhibitors
  • [MeSH-minor] Animals. Apoptosis / drug effects. Clinical Trials as Topic. Cyclooxygenase 1. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Humans. Membrane Proteins. Neovascularization, Pathologic / enzymology. Prostaglandin-Endoperoxide Synthases / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12802790.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA82754; United States / NCI NIH HHS / CA / P30 CA14089; United States / NCI NIH HHS / CA / R01 CA82655
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Number-of-references] 56
  •  go-up   go-down






Advertisement